VCB-1204

VCB-1204 is a preclinical-stage dual chimeric antigen receptor (CAR) T-cell therapy being developed by Vaxcell Bio for the treatment of solid tumors, with a primary focus on hepatocellular carcinoma (HCC). The therapy is engineered to simultaneously target two distinct tumor-associated antigens, Glypican-3 (GPC3) and Epidermal Growth Factor Receptor (EGFR). By utilizing a dual-targeting strategy, VCB-1204 is designed to address the challenge of tumor heterogeneity and mitigate the risk of antigen escape, a common mechanism of resistance where tumor cells evade detection by downregulating a single target antigen. This approach aims to enhance the precision, potency, and durability of the anti-tumor immune response in solid malignancies.

Other names

Vaxcell Bio Dual CAR-T cell therapy